Better Health Labs, Inc. dba Measured

Warning LetterOpen

United StatesIssued Feb 20, 2026Center for Drug Evaluation and Research (CDER)

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations1

Issue DateFeb 20, 2026

Product TypeDrugs

StatusOpen

Letter Details

Firm: Better Health Labs, Inc. dba Measured
Location: United States
FEI Number: N/A
Country: United States
Issue Date: February 20, 2026
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Summary

Better Health Labs, Inc. dba Measured was warned for misbranded compounded semaglutide and tirzepatide products in violation of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of these drugs on its website when it was not, and made misleading claims that its products contained the same active ingredients as FDA-approved drugs like Ozempic, Wegovy, and Mounjaro, implying FDA approval or evaluation when the compounded products had not been approved. The FDA identified violations under sections 502(a) and 502(bb) of the FDCA through a website review conducted in December 2025.

Better Health Labs, Inc. dba Measured FDA Warning Letter, February 20, 2026